Obesity drug boom pushes Novo Nordisk shares to record high

Market value of Danish drugmaker behind Wegovy and Ozempic tops $500bn as demand soars

Novo Nordisk shares hit a record high after the Danish company reported soaring sales of its obesity and diabetes drugs Wegovy and Ozempic, pushing its market value past $500bn and cementing its position as Europe's most valuable company.

Runaway demand for the drugs, which are taken by celebrities including Oprah Winfrey and Elon Musk, has left the company struggling to keep up with orders and scrambling to expand production sites.